Aspirin and clopidogrel are known to reduce early recurrence of stroke, but the benefits do not last. A new study aimed to determine the efficacy and safety of cilostazol dual therapy with cilostazol for...
There are currently no FDA-approved therapeutics for treating NAFLD, but many options are on the horizon. Steven Grinspoon, MD, discussed the options in this session.
In a phase 3 trial, inebilizumab, a monoclonal antibody targeting CD19+ B cells, reduced flare rates and improved treatment-free and glucocorticoid-free remission in patients with immunoglobulin G4-related...
